30.01.19
We are pleased to share the latest update from Orphazyme entitled 'Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)'.
Read more11.01.19
CTD Holdings: Annual conference offers opportunities for academic researchers and industry representatives to exchange information on novel therapeutic interventions...
Read more